BREAKING
AutoZone (AZO) Q2 2026 earnings decline despite 8% sales growth 13 hours ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 2 days ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 2 days ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 2 days ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 5 days ago Zoom Communications Q4 2025 Earnings Results 6 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 6 days ago Synopsys Q1 2026 Earnings Results 6 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 6 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 6 days ago AutoZone (AZO) Q2 2026 earnings decline despite 8% sales growth 13 hours ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 2 days ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 2 days ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 2 days ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 5 days ago Zoom Communications Q4 2025 Earnings Results 6 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 6 days ago Synopsys Q1 2026 Earnings Results 6 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 6 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 6 days ago
ADVERTISEMENT
AlphaGraphs

Trxade (MEDS) delivers another quarter of strong revenue growth

Trxade (NASDAQ: MEDS) on Monday posted a 174% increase in third-quarter revenues to $6.3 million, riding on continued strength in PPE sales. The top-line was way ahead of the average Wall Street consensus of $3.01 million.  Meanwhile, net income came in at $0.02 per share, a cent shy of the street consensus. CEO Suren Ajjarapu […]

$MEDS October 26, 2020 1 min read
NYSE
$MEDS · Earnings

Trxade (NASDAQ: MEDS) on Monday posted a 174% increase in third-quarter revenues to $6.3 million, riding on continued strength in PPE sales. The top-line was way ahead of the average Wall Street consensus of $3.01 million.  Meanwhile, net income came in at $0.02 per share, a cent shy of the street consensus. CEO Suren Ajjarapu […]

· October 26, 2020

Trxade (NASDAQ: MEDS) on Monday posted a 174% increase in third-quarter revenues to $6.3 million, riding on continued strength in PPE sales. The top-line was way ahead of the average Wall Street consensus of $3.01 million. 

Meanwhile, net income came in at $0.02 per share, a cent shy of the street consensus.

Trxade Group Q3 2020 earnings

CEO Suren Ajjarapu said in a statement, “The COVID-19 pandemic has only underscored the importance of an integrated platform like ours, which enables independent pharmacies to remain competitive and profitable in a changing drug procurement marketplace.”

MEDS stock shot up 34% during after-market hours on the stronger-than-expected revenues. The stock has declined 18% since the beginning of this year.

In the third quarter, the Tampa, Florida-based firm added 144 new independent pharmacies to its network. The company now has approximately 11,800 registered pharmacy members.

ADVERTISEMENT

Trxade, which brings together independent pharmacies under one umbrella through its web-based purchasing platform, is present in all 50 states and is rapidly adding pharmacies to its network.

Prior performance

ADVERTISEMENT